Lindahl advises Corline Biomedical AB on directed share issue
Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.
Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.
Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.
Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.
Do you want to know more? Contact:
Mattias Prage
Partner | AdvokatOlle Swärd Brattström
AssociateCarousel items
-
Knowledge
10/23/2026
The board's scope for action in the event of a liquidity shortfall – step by step
The board's scope for action narrows step by step during a liquidity shortfall. We outline the duties – from a solvent company to insolvency.
-
News articles
10/14/2026
Lindahl once again recognised by IFLR1000
Lindahl is ranked in six practice areas in the latest IFLR1000 rankings, including a new ranking for Private equity. Seven of the firm's lawyers also receive individual recognition.
-
Cases and transactions
10/2/2026
Lindahl advises NordAmps AB (publ) on listing on Nasdaq First North Growth Market
Lindahl has acted as legal counsel to NordAmps AB (publ) in connection with the company’s listing on Nasdaq First North Growth Market.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Read more news and insights?
